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The controlled oligomerization of functional proteins at the nanoscale offers the 
possibility to design and produce, by recombinant DNA technologies and in cell factories, 
improved materials and drugs in form of nanoparticles. A recombinant version of the 
scorpion toxin chlorotoxin (CTX), which has attracted interest due to its ability to 
preferentially bind cancer cells, has been engineered to self-assemble as regular 12 nm-
nanoparticles that penetrate cultured cells with the same receptor-specificity than the 
natural toxin. These materials, that appear as promising, biocompatible and 
biodegradable drug carriers for cell-targeted therapy of glioma also exhibit a mild but still 
significant cytotoxic activity associated to the recombinant toxin, that simultaneously acts 
as both driver and therapeutic agent. In addition, the manipulation of the CTX-flanking 
regions shows a potent impact on the performance of the nanoparticles, supporting a 
high functional versatility of CTX-based constructs, regulatable by conventional genetic 
engineering and adaptable to specific therapeutic situations. 
 
 





Cytotoxic proteins have a wide applicability in human therapies, especially in those 
conditions that require efficient and selective cell killing, such as cancer [1]. Chlorotoxin 
(CTX) is a small (4 kDa) basic peptide from the venom of the yellow scorpion Leiurus 
quinquestriatus [2], which blocks small-conductance chloride channels [3] thus 
paralyzing the scorpion prey. Being not extremely potent as a cytotoxin (for instance 
when compared to ribosome-inactivating proteins), it has gained interest as targeting 
agent, as the peptide shows a preferential binding to glioma cells mediated by the cell 
surface matrix metalloproteinase-2 (MMP-2) and the annexin-2. The expression of these 
proteins is increased in gliomas and other cancer cell types [4]. Upon exposure, CTX 
blocks the chloride channel activity but it also inhibits and downregulates MMP-2 [5], 
hampering the glioma tissue migration and invasion potency and inhibiting the 
metastasis [6]. Despite the efforts to develop chlorotoxin-derivatives and analogues that 
may enhance the cytotoxic effect of the natural peptide, the most promising strategy to 
improve patient mean survival time appears to be the use of chlorotoxin as a targeting 
agent for the delivery of anti-tumor agents. In this context, CTX has been explored in 
drug delivery as a component of drug formulations that have entered in clinical trials or 
are already FDA-approved [7]. Indeed, CTX has been largely explored as a partner in 
drug conjugates [8] or in form of fusion proteins [9] for the treatment and diagnosis of 
gliomas and other malignant tumors.  
Recently, we have developed a protein engineering platform based on functional 
recruitment [10] to promote the self-assembly of reporter proteins such as the green 
fluorescent proteins (GFP) [11], and of therapeutic proteins such as pro-apoptotic factors 
[12] or microbial [13] and plant toxins [14] in form of therapeutic or theranostic 
nanoparticles [15]. These category of constructs, based on the fusion of N-terminal 
cationic stretches [16], form fully functional non-amyloid nanoparticles (ranging from ~10 
to 60 nm) [17], that are highly stable upon in vivo administration and show a proper 
biodistrubution and accumulation in tumoral tissues [15, 18]. Lacking natural cell-
targeting properties, these constructs have been genetically empowered to bind CXCR4+ 
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cells by the addition of the CXCR4-binding peptide T22 [19]. We were interested in 
knowing how a protein-only nanostructured version of CTX would keep the cell binding 
and internalization abilities of this peptide. 
In this context, we designed the modular protein CTX-GFP-H6 (Figure 1; see all used 
methods in the Supplementary Information). Being cationic, CTX was expected to act as 
an architectonic tag in combination with the carboxy terminal histidine tail. In addition, 
we were interested in investigating whether CTX might retain its natural biological 
activities as a targeting agent in such a macromolecular organization. Since the cationic 
character of CTX is only moderate, we generated the alternative fusion CTX-KRKRK-
GFP-H6, in which additional cationic residues were inserted between CTX and GFP 
(Figure 1A), to favour nanoparticle formation. Such strategy was previously observed as 
useful to promote oligomerization of blood-brain-barrier (BBB) crossing peptides as 
brain-targeted, protein-only nanoparticles [20]. These two CTX-containing proteins were 
produced and stored in carbonate buffer, which had been previously shown to be optimal 
for the stability of self-assembling protein nanoparticles in cell cultures [13]. We also 
tested two salt concentrations, as the ionic strength might have a significant role in 
nanoparticle formation [18]. As observed in the inset (Figure 1 A), both proteins were 
produced in bacteria as a single molecular species of the expected molecular mass, and 
spontaneously assembling as regular nanoparticles of ~12 nm (Figure 1 B, C). The 
addition of SDS, that promotes the disassembly of protein-only nanoparticles, revealed 
the actual size of the building blocks (around 3.8-5 nm, probably protein monomers 
and/or dimers), very similar to that of the parental GFP-H6 (5.4 nm, probably dimers, 
Figure 1 D). The salt content did not have any detectable impact on the particle size and 
stability but the buffer with salt seemed to promote or increase nanoparticle density or 
amount (Figure 1 B, C). A rich culture media such as Optipro did not show any significant 
impact on the size of the materials, while 10 % BSA decreased the particle size, probably 
by slightly destabilizing protein-protein contacts without inducing their full disassembling 
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(Figure 1 D). The resulting nanoparticles were fully fluorescent, with specific emission 
values of 2550.6 ± 2.8 units/µg and 2027.8 ± 8.1 units/µg for CTX-GFP-H6 and CTX-
KRKRK-GFP-H6 respectively (not shown). Such intrinsic fluorescence emission allowed 
the monitoring of the materials in subsequent assays in cell cultures.  
 
Figure 1. Modular organization of CTX-based building blocks and nanoparticle 
characterization. A. Schematic representation of the fusion proteins showing the amino 
acid sequences, where CTX (green) is placed at the amino termini and a hexahistidine 
tail (H6, blue) at the carboxy termini. Linker regions (purple) were placed in both cases 
between CTX and GFP (grey), to ensure fluorescence emission of the fusion protein. A 
cationic (red) region was intersected in CTX-KRKRK-GFP-H6 downstream the CTX. 
Siding amino acid sequences, we show the Comassie blue staining of proteins upon 
elution from affinity chromatography and PAGE. Relevant molecular weight markers are 
indicated. At the bottom, the molecular weights of the whole constructs as determined 
by MALDI. B. FESEM images of purified protein, showing their nanoarchitecture. 
Particles were diluted in two buffers, in which nanoparticles were tested for stability, 
namely carbonate buffer (C) and carbonate buffer plus 333 mM NaCl (C+S). Bar size is 
20 nm in all panels. C. DLS plots showing the hydrodynamic size of nanoparticles. The 
peak value and the polydispersion index (Pdi) are indicated. Determinations were done 
on the material dissolved in carbonate buffer (C) and carbonate buffer plus 333 mM NaCl 
(C+S). D. The hydrodynamic size of the particles in these buffers was also determined 
in presence of BSA 10 % and in Optipro cell culture medium. SDS (at 1 %), that promotes 
the disassembling of protein-only nanoparticles was alternatively added to the buffer to 
identify the size of the building blocks. The size of the parental GFP-H6 is also indicated 
in nm. Untreated nanoparticles are shown by coloured plots. All the experiments were 
performed at pH 8. The peak value of the samples in SDS, BSA and Optipro are specified 
over the respective plots. 
 
The spontaneous self-assembling of the engineered CTX, in both versions, prompted us 
to further investigate whether the toxin, in such oligomeric form, could mediate cell 
binding and internalization. Two cell lines previously identified as targets for CTX, namely 
HeLa (overexpressing annexin-2) and U87MG (overexpressing MMP2) [21-24], were 
selected to examine cell penetrability of the nanoconstructs, using the intrinsic green 
fluorescence as a monitoring tool. As observed (Figure 2A), CTX-KRKRK-GFP-H6 
nanoparticles were much more efficient than CTX-GFP-H6 in cell internalization, in both 
cell lines. Moreover, regarding to the CTX-KRKRK-GFP-H6 protein version, a high salt 
content was significantly improving cell penetration of the material, in particular when 
6 
 
observing the uptake in U87MG cultures. In this cell line, penetrability of the protein 
nanoparticles was globally much higher than in HeLa cell line.  
To ensure that CTX, in form of nanoparticles, had not lost its cell targeting activities we 
explored the selectivity of cell penetrability by inhibiting annexin-2 binding during cell 
interaction. As observed (Figure 2B), cell uptake in HeLa cells was significantly reduced 
by both a monoclonal antibody and a polyclonal serum against the cell surface protein 
acting as a CTX receptor. Since the antibodies acted over the penetration of both 
proteins in both buffers, we deduced that both the cationic stretch added to CTX-KRKRK-
GFP-H6 and the high salt content enhanced the penetrability of the protein (Figure 2A) 
by a receptor-dependent mechanism (Figure 2B). Both cell penetrability and receptor 
specificity were observed at levels comparable to those shown by T22-GFP-H6 (Figure 
2 C). This protein contains the peptide T22 that selectively and uniquely binds the cell 
surface cytokine receptor CXCR4, expressed in HeLa cells [19]. In that case, inhibition 
of cell uptake by the CXCR4 antagonist AMD3100 [25] was more effective than the 
mediated by the anti-annexin-2 antibodies over CTX-carrying constructs probably 
because the unique target of T22 compared to the dual binding sites of CTX. On the 
other hand, GFP-H6 was unable to penetrate cultured cells (Figure 2 C), supporting 
again the role of CTX in the penetrability of the nanoparticles. 
 
Figure 2. Cell penetrability of CTX-based nanoparticles. A. Internalized nanoparticles in 
two alternative cell lines, namely HeLa and U87MG cells, 24 h after exposure to different 
protein amounts. Intracellular fluorescence was corrected by the specific emission to 
result in data representative of protein amounts. Cells were submitted to a harsh trypsin 
treatment before measurements to remove externally attached protein as described [26]. 
Nanoparticles were administered as dissolved in either carbonate (C) or carbonate with 
NaCl (C +S) buffer. Y axis scales might be not precisely comparable. B. Selective 
antibody-mediated inhibition of nanoparticle uptake in HeLa cells, by an anti-annexin-2 
monoclonal antibody (mAb) and polyclonal antibody (pAb). The statistical analysis was 
performed using an ANOVA Tukey’s multiple comparisons test (*p < 0.05; **p < 0.01). 
Normality was confirmed by Shapiro-Wilk W where p˃0.05. Comparisons were done 
always with samples without antibody. C. Internalization of the related CXCR4-binding 
T22-GFP-H6 nanoparticles in (CXCR4+) HeLa cells, and inhibition by the CXCR4 
antagonist AMD3100 at an excess molar ratio 10:1. The parental GFP-H6 protein is 
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unable to enter cultured cells.  All the experiments using HeLa cells were performed at 
pH 7.0-7.4, and those using U87 cells at pH 6.8-7.2. 
 
 
At this stage, we determined the viability of cells exposed to CTX nanoparticles. Although 
classified as a toxin, chlorotoxin has displayed no obvious cytoxicity when administered 
to humans, which is important for drug development. Indeed, biological activities of 
chlorotoxin are mainly related with targeting ability, inhibition of migration and invasion 
of glioma cells and also, with antiangiogenic properties [27].  
 
Unexpectedly (Figure 3), the nanostructured CTX-GFP-H6 had a significant cytotoxic 
impact on both lines, being the CTX-KRKRK-GFP-H6 version more cytotoxic than its 
counterpart CTX-GFP-H6, and U87MG cells more sensitive than HeLa. CTX-GFP-H6, 
when added to 0.1 µM, had a surprising but robust positive impact on cell viability, the 
number of viable cells reaching 120 % of the control samples. This fact was not observed 
in U87MG cells (Figure 3 B), in which cell death was only moderate, dose-independent, 
protein-independent, although significantly modulated by the salt content of the protein 
storage buffer. The toxicity of CTX was milder than that of the potent microbial toxin 
PE24 from Pseudomonas aeruginosa [13] (Figure 3 C), while the CXT-less GFP-H6 
showed no effect on cultured cells (Figure 3 C). 
 
 
Figure 3. Cell viability upon exposure to CTX-based nanoparticles. HeLa cells (A) and 
U87MG cells (B) were exposed to protein nanoparticles for 72 h. Nanoparticles were 
administered as dissolved in either carbonate (C) or carbonate with NaCl (C +S) buffer. 
The statistical analysis was performed using an ANOVA Tukey’s multiple comparisons 
test (*p < 0.05; **p < 0.01). Normality was confirmed by Shapiro-Wilk W where p˃0.05. 
Symbols at the top of the bars indicate the comparison with the control (100 %). Symbols 
at the left of the bars indicate comparisons between protein pairs, indicated by withe 
linkers. C) HeLa cell viability upon exposure to control, non-toxic GFP-H6 protein and 
cytotoxic T22-PE24-H6 nanoparticles. All the experiments using HeLa cells were 




In summary, we have constructed two recombinant versions of CTX, that fused to a His-
tagged GFP assemble as stable, fully fluorescent protein nanoparticles of regular size 
(12 nm, Figure 1). In this oligomeric form, the protein retains its ability to penetrate target 
cells, as determined here in two cell lines that display suitable receptors for CTX, namely 
HeLa and U87MG [21, 23, 24, 28]. The cell uptake is receptor-dependent, as it is 
inhibited when annexin-2 is sterically blocked by both a monoclonal antibody and an anti-
annexin-2 sera (Figure 2 B). The CTX version that contains some additional cationic 
residues (KRKRK, Figure 1) inserted between the targeting peptide and GFP, shows an 
enhanced cell penetrability when compared with the plain CTX fusion (Figure 2 A). Since 
the uptake of the cationic construct is still receptor-mediated (Figure 2 B), it cannot be 
merely attributed to a higher electrostatic affinity of the nanoparticles to the cell 
membrane. In fact, it has been reported that single amino acid substitutions (Lys to Arg) 
that enhance the cationic nature of CTX result in a more stable version of the peptide 
and in an enhanced cell penetrability, probably associated to such higher structural 
stability [7]. Interestingly, the presence of salt dramatically enhances up to three fold the 
already improved cell penetrability of the cationic CTX version (Figure 2 A) that is 
accompanied by a slight tendency to an increased cytotoxicity in vitro, at least in HeLa 
cells (Figure 3).  
Importantly, the nanostructured version of CTX retains the tumor cell-targeting properties 
of this protein, with high cell level of specificity, and excellent cell penetrability. In 
addition, a mild but significant cytotoxicity is associated to the constructs. The cell killing 
properties of the CTX nanoparticles appear to slightly be cell line dependent, and also 
influenced by the engineered cationic segments and by the salt content of the media 
(Figure 3). In this regard, both CTX nanoparticle versions developed here appear as 
promising biocompatible and biodegradable carrier systems to load anticancer drugs or 
therapeutic proteins for targeted therapy of glioma. However, in addition, the unexpected 
dual role of CTX as driver and cell killing agent is highly promising for a true functional 
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recruitment in the generation of nanostructured, multifunctional and smart therapeutics 
[10]. This is also in the line of designing chemically homogeneous vehicle-free drugs, at 
the nanoscale, that is now an emerging and appealing concept in the context of 
innovative tumor targeted drugs [29].  
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